
By protecting biodiversity and natural ecosystems, the pharmaceutical industry can mitigate risks and build long-term resilience.
Despite its vital role in global healthcare, the pharmaceutical industry faces growing risks due to its deep dependence on nature. With 70% of medicines derived from natural sources, biodiversity loss and ecosystem degradation threaten future drug discovery, supply chain stability, and long-term business resilience.
Quantis US Lead for Cosmetics + Personal Care and Pharma, Clement Turnier explores the connection between pharmaceuticals and nature, outlining key environmental risks and the frameworks that can help companies integrate nature into their sustainability strategies. From regulatory pressures to supply chain disruptions, he highlights how businesses can take action to build resilience and drive sustainable success.
Latest resources

What nature-related risks does the pharma industry face?
By protecting biodiversity and natural ecosystems, the pharmaceutical industry can mitigate risks and build long-term resilience.

World Cocoa Foundation publishes first ever greenhouse gas accounting standard for the cocoa sector
World Cocoa Foundation & Quantis launch first-ever GHG standard, helping the cocoa sector measure, report, and cut emissions consistently.

Accelerating decarbonization
Allon Zeitoun and Géraldine Noé sit down to discuss the progress made, challenges ahead and what companies can do to accelerate action to 2030